OTCMKTS:CRPOF Ceapro (CRPOF) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free CRPOF Stock Alerts $0.17 0.00 (0.00%) (As of 06/6/2024) Add Compare Share Share Today's Range$0.17▼$0.1750-Day Range$0.17▼$0.2252-Week Range$0.11▼$0.40VolumeN/AAverage Volume15,466 shsMarket Capitalization$13.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get Ceapro alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Ceapro Stock (OTCMKTS:CRPOF)Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.Read More CRPOF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRPOF Stock News HeadlinesJune 3, 2024 | globenewswire.comAeterna Zentaris and Ceapro Complete Merger TransactionMay 29, 2024 | globenewswire.comCeapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateApril 29, 2024 | globenewswire.comCeapro Inc. Reports 2023 Financial Results and Operational HighlightsMarch 28, 2024 | finanznachrichten.deAeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 28, 2024 | globenewswire.comCeapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 12, 2024 | globenewswire.comAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsFebruary 26, 2024 | globenewswire.comLeading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyFebruary 23, 2024 | globenewswire.comCeapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base BusinessFebruary 15, 2024 | globenewswire.comCeapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna ZentarisDecember 13, 2023 | finance.yahoo.comCeapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based DiseasesNovember 29, 2023 | msn.comCeapro GAAP EPS of -C$0.01, revenue of C$2.62MNovember 7, 2023 | finance.yahoo.comCeapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) TechnologyJuly 18, 2023 | finance.yahoo.comCeapro Announces Next Phase of Research Collaboration with the Angiogenesis FoundationJune 7, 2023 | finanznachrichten.deCeapro Inc.: Ceapro Announces Results of 2023 Shareholders' MeetingJune 7, 2023 | finance.yahoo.comCeapro Announces Results of 2023 Shareholders’ MeetingApril 27, 2023 | finance.yahoo.comCeapro Inc. Appoints Michel Regnier as Senior Vice President, Technical OperationsApril 26, 2023 | theglobeandmail.comClosing Bell: Ceapro Inc flat on Tuesday (CZO)April 25, 2023 | theglobeandmail.comClosing Bell: Ceapro Inc flat on Monday (CZO)April 13, 2023 | theglobeandmail.comClosing Bell: Ceapro Inc down on Thursday (CZO)March 23, 2023 | finance.yahoo.comCeapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International ConferenceMarch 14, 2023 | finance.yahoo.comCeapro Inc. (CRPOF) Stock Historical Prices & Data - Yahoo FinanceMarch 8, 2023 | finance.yahoo.comCeapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American SocietyFebruary 21, 2023 | finance.yahoo.comCeapro Inc. Recognized as a Top 50 TSX Venture Exchange CompanyJanuary 10, 2023 | finance.yahoo.comCeapro to Present at the Virtual Investor 2023 Companies to Watch EventDecember 22, 2022 | msn.comCeapro receives approval to begin human trial for anti-inflammatory drugSee More Headlines Receive CRPOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ceapro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/29/2024Today6/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CRPOF CUSIPN/A CIKN/A Webwww.ceapro.com Phone(780) 421-4555Fax780-421-1320EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,490,000.00 Net Margins-69.60% Pretax Margin-31.44% Return on Equity-20.30% Return on Assets-18.07% Debt Debt-to-Equity RatioN/A Current Ratio11.00 Quick Ratio7.72 Sales & Book Value Annual Sales$7.14 million Price / Sales1.86 Cash Flow$0.06 per share Price / Cash Flow2.74 Book Value$0.32 per share Price / Book0.53Miscellaneous Outstanding Shares78,293,000Free FloatN/AMarket Cap$13.31 million OptionableNot Optionable Beta1.47 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Gilles R. Gagnon ICD.D (Age 70)M.B.A., M.Sc., CEO, President & Director Comp: $409.89kMs. Stacy Prefontaine C.A.CPA, CA, CPA, CFO & Corporate SecretaryDr. Bernhard SeifriedSenior Director of Research & TechnologyMr. Michel Regnier P. Eng.Senior Vice President of Technical OperationsKey CompetitorsAnebulo PharmaceuticalsNASDAQ:ANEBKezar Life SciencesNASDAQ:KZRDaré BioscienceNASDAQ:DAREEagle PharmaceuticalsNASDAQ:EGRXNabriva TherapeuticsNASDAQ:NBRVView All Competitors CRPOF Stock Analysis - Frequently Asked Questions How have CRPOF shares performed in 2024? Ceapro's stock was trading at $0.1652 at the beginning of 2024. Since then, CRPOF shares have increased by 2.9% and is now trading at $0.17. View the best growth stocks for 2024 here. How were Ceapro's earnings last quarter? Ceapro Inc. (OTCMKTS:CRPOF) released its earnings results on Wednesday, May, 29th. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $2.06 million for the quarter. Ceapro had a negative net margin of 69.60% and a negative trailing twelve-month return on equity of 20.30%. How do I buy shares of Ceapro? Shares of CRPOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CRPOF) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ceapro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ceapro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.